Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Osmanov Ismail M, Spiridonova Ekaterina, Bobkova Polina, Gamirova Aysylu, Shikhaleva Anastasia, Andreeva Margarita, Blyuss Oleg, El-Taravi Yasmin, DunnGalvin Audrey, Comberiati Pasquale, Peroni Diego G, Apfelbacher Christian, Genuneit Jon, Mazankova Lyudmila, Miroshina Alexandra, Chistyakova Evgeniya, Samitova Elmira, Borzakova Svetlana, Bondarenko Elena, Korsunskiy Anatoliy A, Konova Irina, Hanson Sarah Wulf, Carson Gail, Sigfrid Louise, Scott Janet T, Greenhawt Matthew, Whittaker Elizabeth A, Garralda Elena, Swann Olivia V, Buonsenso Danilo, Nicholls Dasha E, Simpson Frances, Jones Christina, Semple Malcolm G, Warner John O, Vos Theo, Olliaro Piero, Munblit Daniel, and the Sechenov StopCOVID Research Team
Аннотация
METHODS: This is a prospective cohort study of children (≤18 years old) admitted to hospital with confirmed COVID-19. Children admitted between 2 April 2020 and 26 August 2020 were included. Telephone interviews used the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 Health and Wellbeing Follow-up Survey for Children. Persistent symptoms (>5 months) were further categorised by system(s) involved.
RESULTS: 518 out of 853 (61%) eligible children were available for the follow-up assessment and included in the study. Median (interquartile range (IQR)) age was 10.4 (3-15.2) years and 270 (52.1%) were girls. Median (IQR) follow-up since hospital discharge was 256 (223-271) days. At the time of the follow-up interview 126 (24.3%) participants reported persistent symptoms, among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%) and sensory problems (29, 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: older age "6-11 years" (OR 2.74, 95% CI 1.37-5.75) and "12-18 years" (OR 2.68, 95% CI 1.41-5.4), and a history of allergic diseases (OR 1.67, 95% CI 1.04-2.67).
CONCLUSIONS: A quarter of children experienced persistent symptoms months after hospitalisation with acute COVID-19 infection, with almost one in 10 experiencing multisystem involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up.